Albumin Therapeutics

Albumin Therapeutics is a biotechnology company dedicated to developing recombinant human serum albumin (rHSA) for therapeutic applications. The company's primary focus is its lead candidate, AT-001, a yeast-derived recombinant albumin intended to replace plasma-derived albumin in treating conditions like liver cirrhosis, hypovolemia, and ascites. By leveraging a proprietary production platform, Albumin Therapeutics aims to offer a safer, more consistent, and pathogen-free alternative to traditional blood-derived products. Headquartered in Huntsville, Alabama, the company was established by leaders in protein crystallography to address the global supply constraints and safety concerns associated with human-derived albumin.